Advertisement

Topics

Oligomer Oy Company Profile

14:22 EST 17th December 2018 | BioPortfolio

Nil

Location

Latokartanonkaari 11 D-talo
Helsinki
790
Finland

Contact

Phone: 358- 9- 3478 900
Fax: 358-9- 3478 9090
Email: info@oligomer.fi


News Articles [4 Associated News Articles listed on BioPortfolio]

Amyloid oligomer interactions and polymorphisms: disease-relevant distinct assembly of α-synuclein and tau

Cognition Therapeutics Initiates NIA-Funded SNAP Study of Elayta™ to Measure Toxic Oligomer Displacement and Clearance in Alzheimer's Disease

Pittsburgh, June 05, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheime...

Medical News Today: Alzheimer's: Groundbreaking plan aims to target root cause

Now that scientists agree that oligomer protein deposits cause Alzheimer's, an international team has detailed a plan for developing drugs to target them.

ProMIS Neurosciences Inc.: ProMIS Neurosciences Discusses Critical Importance of Selectively Targeting the Root Cause of Alzheimer's Disease

Narrated white paper reveals lessons learned from 15 years of drug development; pressing need to selectively target the toxic oligomer TORONTO and CAMBRIDGE, Mass., Nov. 06, 2018 In this presentati...

Drugs and Medications [0 Results]

None

PubMed Articles [79 Associated PubMed Articles listed on BioPortfolio]

Preparation of a Well-Defined and Stable β-Barrel Pore-Forming Aβ42 Oligomer.

The formation of amyloid-β peptide (Aβ) oligomers at the cellular membrane is considered a crucial process that underlies neurotoxicity in Alzheimer's disease (AD). To obtain structural information ...

A novel electrochemical aptasensor based on nontarget-induced high accumulation of methylene blue on the surface of electrode for sensing of α-synuclein oligomer.

This study describes a novel electrochemical aptasensor for detection of α-synuclein (α-syn) oligomer, an important biomarker related to Parkinson's and Alzheimer's diseases. The sensing platform is...

Effects of Oligomer Length, Solvents, and Temperature on the Self-Association of Aromatic Oligoamide Foldamers.

The effects of oligomer length, solvent, and temperature on the self-association of stably folded short aromatic oligoamide are probed. With large flat surfaces, these aromatic oligoamides undergo sta...

Oligo(Ethylene Glycol) Length Effect of Water-Soluble Ru-Based Olefin Metathesis Catalysts on Reactivity and Removability.

A study of reaction kinetics and removal efficiency of a family of ruthenium (Ru)-based olefin metathesis catalysts containing ethylene-glycol-oligomer-tethered N-heterocyclic carbene (NHC) ligands ha...

An oligomer-specific antibody improved motor function and attenuated neuropathology in the SOD1-G93A transgenic mouse model of ALS.

Amyotrophic lateral sclerosis (ALS) is a rapidly progressing neurodegenerative disease characterized by motor neuron loss in the brain and spinal cord. Mutations in Cu-Zn superoxide dismutase (SOD1) a...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease

This is a multi‐center, Phase 1b, randomized, double‐blind, placebo‐controlled parallel‐group trial in adults with mild to moderate AD.

Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid

AVI-4020 Injection, a phosphorodiamidate Morpholino oligomer (PMO), was found to cross the blood-brain barrier during a study of patients with presumptive West Nile virus disease. AVI-4065...

Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD), a fatal muscle degenerative disorder, arises from mutations in the dystrophin gene. Antisense therapy with the use of antisense oligonucleotides (AON) ha...

Companies [5 Associated Companies listed on BioPortfolio]

Oligomer Oy

Nil

Bio-Synthesis, Inc.

Bio-Synthesis Inc was the first commercial company providing DNA and peptides in 1984. We specialize in custom peptide synthesis from small to large scale and we can help you design the optimal pepti...

PolyMedix

PolyMedix is the leader in developing biomimetics - novel small molecule, oligomer and polymer protein-mimetic drugs for membrane protein and protein:protein targets. PolyMedix has a proven computatio...

BioChrom Labs, Inc

Established in 1990, BioChrom Labs, Inc., Indiana, USA, is dedicated to developing and manufacturing polymeric materials using patentable and proprietary technologies. HYDROCELL HPLC Columns and packi...

Sarepta Therapeutics

Innovative RNA-Based Technology; First-in-Class Therapeutics Sarepta Therapeutics – formerly AVI BioPharma – remains focused on developing first-in-class, RNA-based therapeutics to imp...

More Information about "Oligomer Oy" on BioPortfolio

We have published hundreds of Oligomer Oy news stories on BioPortfolio along with dozens of Oligomer Oy Clinical Trials and PubMed Articles about Oligomer Oy for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oligomer Oy Companies in our database. You can also find out about relevant Oligomer Oy Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record